Frontlight ResearchEarly access
Taking people in United StatesNo phase
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
Key facts
- Who runs it
- Innova Vascular, Inc.
- Where
- Albany, Birmingham, Bradenton, Chapel Hill, Chicago, Columbus, Dallas, Irvine, Knoxville, Long Beach, Mission Viejo, Naples, Orange, Tampa, Tucson, and Washington D.C., United StatesSee the 16 sitesAlso in 1 other country, 5 sites
- Trial code
- Status
- Recruiting
- People taking part
- 107 people, planned
- Started
- 19 Aug 2024
- Planned end
- Sept 2026
- Type of study
- Interventional
- Treatments tested
- Laguna Thrombectomy System
- Record updated
- 17 July 2026
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 31 criteriaShow less
Who can take part
- ≥ 18 years of age; < 85 years old
- RV/LV ratio > 0.9 as determined by CTA
- Systolic blood pressure > 90 mmHg
- Heart rate ≤ 120
- Patient is deemed eligible for procedure by the interventional investigator
- CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery)
- PE Symptom duration ≤ 14 days
Who cannot take part
- Current participation in another drug or medical device treatment study
- History of prior PE within the past 90 days
- Cardiovascular or pulmonary surgery within the last 7 days
- Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
- In active chemotherapy or radiation treatment for a malignancy during the course of the study
- Known bleeding diathesis or coagulation disorder that cannot be managed with anti-coagulation
- History of known severe or chronic pulmonary arterial hypertension
- History of underlying lung disease that is oxygen dependent
- History of chest irradiation
- Platelets: < 100,000/microliter
- Serum Creatinine: > 2 mg/dL
- International Normalized Ratio (INR): > 3
- History or chronic left heart disease with left ventricular ejection fraction < 30%
- Systolic pulmonary artery pressure > 70 mmHg on initial invasive hemodynamic assessments
- Life expectancy of < 90 days in the opinion of investigator at the time of enrollment
- Subject pregnant or breast feeding
- Any intravascular administration of a fibrinolytic agent (such as Alteplase or Tenecteplase) within the last 30 days
- Presence of recently placed (<8 weeks) intracardiac devices (such as pacemaker leads) in the right ventricle or right atrium
- FiO2 Requirement: > 40% (6 LPM) to keep oxygen saturation > 90%
- Hematocrit: < 28%
- Major Trauma Injury Severity Score (ISS): > 15
- Any absolute contraindication to systemic or therapeutic dosage of heparin or anticoagulants
- Imaging or other evidence that suggests, in the opinion of the investigator, the subject is not appropriate for mechanical thrombectomy intervention (e.g., inability to navigate to target location, predominantly chronic clot or non-clot embolus)
- Known presence of clot in transit within right atrium or ventricle
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Where in United States
Also in 1 other country, 5 sites
- Albany Medical CenterAlbany, United StatesContact: Sanjay Shrivastava, Ph.D.No longer taking part
- Grandview Medical CenterBirmingham, United StatesContact: Sanjay Shrivastava, Ph.D.Taking people
- Manatee Memorial HospitalBradenton, United StatesContact: Sanjay Shrivastava, Ph.D.Taking people
- University of North Carolina at Chapel HillChapel Hill, United StatesContact: Sanjay Shrivastava, Ph.D.Taking people
- Rush University Medical CenterChicago, United StatesContact: Sanjay Shrivastava, Ph.D.No longer taking part
- OhioHealth Research InstituteColumbus, United StatesContact: Sanjay Shrivastava, Ph.D.Taking people
- University of Texas, SouthwesternDallas, United StatesContact: Sanjay Shrivastava, Ph.D.Taking people
- University of California, IrvineIrvine, United StatesContact: Sanjay Shrivastava, Ph.D.Taking people
- Turkey Creek Medical CenterKnoxville, United StatesContact: Sanjay Shrivastava, Ph.D.Taking people
- Memorial Care Long Beach Medical CenterLong Beach, United StatesContact: Sanjay Shrivastava, Ph.D.Taking people
- Mission Hospital Regional Medical CenterMission Viejo, United StatesContact: Sanjay Shrivastava, Ph.D.Taking people
- Physicians Regional Medical CenterNaples, United StatesContact: Sanjay Shrivastava, Ph.D.Taking people
- St. Joseph Hospital of OrangeOrange, United StatesContact: Sanjay Shrivastava, Ph.D.Taking people
- AdventHealth TampaTampa, United StatesContact: Sanjay Shrivastava, Ph.D.No longer taking part
- University of ArizonaTucson, United StatesContact: Sanjay Shrivastava, Ph.D.Taking people
- George Washington UniversityWashington D.C., United StatesContact: Sanjay Shrivastava, Ph.D.Taking people
About the trial
What the trial wants to find out
This is a prospective, multi-center, pivotal study to demonstrate the safety and effectiveness of the Laguna Thrombectomy System for the treatment of pulmonary embolism. The Laguna Thrombectomy System is an investigational device which consists of the Laguna Clot Retriever™ System and the Malibu Aspiration Catheter™ System. These devices are manufactured by Innova Vascular, Inc.
The group in the trial
- Laguna Thrombectomy SystemTreatment being tested
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Fit questions
- Built from NCT06041594, who can take part
- Record updated
- 17 July 2026